

Highlights 2017



netherlands
pharmacovigilance
centre **lareb**

Reports

The Netherlands Pharmacovigilance Centre Lareb identifies risks associated with the use of medicines in daily practice and is the knowledge centre for adverse drug reactions (ADRs) and adverse events following immunisation (AEFI). Lareb collects 20.000 to 25.000 reports of ADRs yearly. Since 2010 the number of reports by patients, Healthcare professionals (HCP) and industry has more than doubled. Analysis of the ADR reports led to 29 signals in 2017.

Reported ADRs by HCPs and patients

10.992




Reported AEFIs by HCPs and patients

1.785




Numbers of reports by patients, HCP and industry 2001-2017



Reporters

Percentage of reports per group in 2017

A Patients	55%	E Nurses	4%
B Medical specialists	21%	F Public health specialists	2%
C Pharmacists	10%	G Other Healthcare professionals	1%
D General practitioners	6%	H Hospital pharmacists	1%



Lareb Intensive Monitoring

In addition to the spontaneous reporting system, Lareb also runs an intensive monitoring program called Lareb Intensive Monitoring (LIM). This program comprises observational prospective cohort studies in which real world data is actively collected in a population with one common characteristic (e.g. similar medication use or disease). The goal of LIM is to monitor the use and safety of drugs on short term. Thereby providing actionable knowledge resulting in improvement of pharmacotherapy and management of expectations regarding adverse drug reactions for both HCPs and patients. Patients register online and receive web-based questionnaires on predefined moments in time. Information collected concerns patient characteristics, actual drug use, possible adverse effects and related aspects like course, treatment, burden and risk factors.

In 2017, the LIM study on new oral anticoagulants was continued. Like previous years, the seasonal influenza vaccination has been monitored. The LIM infrastructure has also been deployed for the Monitor Biologicals that started off in 2017. In total 1431 new patients have been included in these LIM-studies.

Monitored by LIM


Studies

4



New participants

1.431



Signals

Based on the analyses of ADR reports, 29 signals were detected.

- | | |
|--|---|
| 1. Metabole acidose met hoge aniongap (HAGMA) door interactie tussen paracetamol en flucloxacilline - Update cases | 17. Calcipotriol betamethason foam and sticky hair |
| 2. Salmeterol with fluticasone and lack of efficacy after drug substitution | 18. Paroxetine and bruxism |
| 3. Dexamfetamine and Raynaud | 19. Methylphenidate and lack of efficacy after drug substitution |
| 4. Overview of completed suicides with varenicline | 20. DOACs and cholesterol embolism |
| 5. Mesalazine and photosensitivity | 21. Overview on Red Yeast Rice |
| 6. Update Overview on Cervarix® | 22. Jaarrapport 2016: Bijwerkingen na vaccinaties in het kader van het Rijksvaccinatieprogramma |
| 7. Dalteparine, nadroprine, enoxoparine and headache | 23. Meldingen van bijwerkingen na influenzavaccinaties - Rapportage Influenza seizoen 2016-2017 |
| 8. Midalgan® en buikpijn | 24. Prevalin direct® neusspray –verwarring naamgeving |
| 9. Overview on direct anticoagulants -update 2017 | 25. Salbutamol and hallucinations |
| 10. Omnipod Ysomed Pump and application site reactions | 26. Decreased international normalised ratio (INR) associated with substitution of acenocoumarol from the manufacturer Sandoz to acenocoumarol from the manufacturer Centrafarm |
| 11. Off-label use of methylphenidate in adults | 27. Omeprazole suspension and regurgitated gastric content discoloured |
| 12. Dasatinib and nephrotic syndrome | 28. Levodopa/carbidopa en verpulverde tabletten |
| 13. Overview on reports of drug substitution | 29. Pipamperone and increased appetite and increased weight |
| 14. Abdominal pain, chest pain and headache while using noscapine | |
| 15. Phyto-estrogens with hop and soy and post-menopausal bleeding | |
| 16. Tabex® and psychosis | |

Knowledge centre

(Inter)national publications

83



Publications lay press

81



TV/Radio broadcasts

4



Newsletter subscribers

11.864



Lareb appeared regularly in the news. For example about the use of methylphenidate in adults, adverse drug reactions of red yeast rice and the effects on the coagulation time after substitution of acenocoumarol into another brand.

Information requests

1.875



Lectures

50



Presentations

14



Congres booths

10



Teratology Information Service (TIS)

TIS is Lareb's knowledge centre for medication use during pregnancy and lactation.

Information requests

1.707



pREGnant

With the Dutch Pregnancy Drug Register pREGnant, Lareb aims to get more insight in medication use during pregnancy and breastfeeding and the safety regarding the health of the fetus / infant as the health of the pregnant woman. In 2017, 800 pregnant women were enrolled, whereas the total number of participants in pREGnant was 3264 at the end of 2017. Currently, steps are taken to implement the pREGnant-register on large scale.

New participants

800



Participants in total

3.264



Goudsbloemvallei 7
5237 MH 's-Hertogenbosch
The Netherlands
+31 73 64 69 700
info@lareb.nl
www.lareb.nl